title: Viral neuroinvasion as a marker for BBB integrity following exposure to cholinesterase inhibitors.
abstract: Exposure to the nerve agent soman, an irreversible cholinesterase (ChE) inhibitor, results in changes in blood-brain barrier permeability attributed to its seizure-induced activity. However, smaller BBB changes may be independent of convulsions. Such minor injury may escape detection. A nonneuroinvasive neurovirulent Sindbis virus strain (SVN) was used as a marker for BBB permeability. Peripheral inoculation of mice with 2 x 10(3) plaque forming units (PFU) caused up to 10(5) PFU/ml viremia after 24 hours with no signs of central nervous system (CNS) infection and with no virus detected in brain tissue. Intra-cerebral injection of as low as 1-5 PFU of the same virus caused CNS infection, exhibited 5-7 days later as hind limb paralysis and death. Soman (0.1-0.7 of the LD50) was administered at peak viremia (1 day following peripheral inoculation). Sublethal soman exposure at as low as 0.1 LD50 resulted in CNS infection 6-8 days following inoculation in 30-40% of the mice. High virus titer were recorded in brain tissue of sick mice while no virus was detected in healthy mice subjected to the same treatment. No changes in the level of viremia or changes in viral traits were observed in the infected mice. The reversible anticholinesterases physostigmine (0.2 mg/kg, s.c.) and pyridostigmine (0.4 mg/kg, i.m.) injected at a dose equal to 0.1 LD50, induced similar results. Thus, both central and peripheral anticholinesterases (anti-ChEs) induce changes in BBB permeability sufficient to allow, at least in some of the mice, the invasion of this otherwise noninvasive but highly neurovirulent virus. This BBB change is probably due to the presence of cholinesterases in the capillary wall. SVN brain invasion served here as a highly sensitive and reliable marker for BBB integrity.
authors.affiliation: Israel Institute for Biological Research, Ness-Ziona. ettie@iibr.gov.il
authors.forename: E
authors.initials: E
authors.lastname: Grauer
authors.forename: D
authors.initials: D
authors.lastname: Ben Nathan
authors.forename: S
authors.initials: S
authors.lastname: Lustig
authors.forename: D
authors.initials: D
authors.lastname: Kobiler
authors.forename: J
authors.initials: J
authors.lastname: Kapon
authors.forename: H D
authors.initials: HD
authors.lastname: Danenberg
mesh_terms: D018354:Alphavirus Infections / Q000097:blood* / Q000821:virology; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000502:physiology; D001921:Brain / Q000821:virology*; D002493:Central Nervous System Diseases / Q000821:virology; D002800:Cholinesterase Inhibitors / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007928:Lethal Dose 50; D051379:Mice; D008813:Mice, Inbred ICR; D010539:Permeability / Q000187:drug effects; D010830:Physostigmine / Q000633:toxicity; D011729:Pyridostigmine Bromide / Q000633:toxicity; D012845:Sindbis Virus; D012999:Soman / Q000633:toxicity*; D014766:Viremia / Q000097:blood / Q000821:virology
chemical_list: D002800:Cholinesterase Inhibitors; D012999:Soman; D010830:Physostigmine; D011729:Pyridostigmine Bromide